TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15314861

Group type: EXPERIMENTAL
Intervention: Epitalamin (bioregulator of the cytomedine class)
Number of subjects: 0
Study: 11343009

Group type: EXPERIMENTAL
Intervention: Reusing suction catheters for a 24-hour period (n = 241)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Using a new catheter for each episode of suctioning (n = 245)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Cost analysis of reusing suction catheters
Number of subjects: 486
Study: 9750805

Group type: EXPERIMENTAL
Intervention: Brachial plexus block using a peripheral nerve stimulator (group St)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Transarterial brachial plexus blockade with injection of 2/3 of the anaesthetic in back of and 1/3 in front of the artery (group TAP)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Transarterial brachial plexus blockade with one single injection in back of the artery (group TP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nerve stimulator (group St)
Number of subjects: 111
Study: 7941992

Group type: EXPERIMENTAL
Intervention: Endocrine treatment (medroxy-progesterone acetate 30 mg weekly and Tamoxifen 300 mg weekly)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Radiation treatment (external beam photon treatment of the whole pelvis, average total dose of 3680 cGy rad)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 43
Study: 3295547

Group type: EXPERIMENTAL
Intervention: Multipolar electrocoagulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham multipolar electrocoagulation
Number of subjects: 44
Study: 31578771

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily for 6 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 26
Study: 30027292

Group type: EXPERIMENTAL
Intervention: C‐509T allele in TGFB1
Number of subjects: 287

Group type: COMPARATOR
Intervention: No C‐509T allele in TGFB1
Number of subjects: 287
Study: 27084290

Group type: EXPERIMENTAL
Intervention: Suspend before low feature of the Medtronic MiniMed 640G pump
Number of subjects: 0

Group type: COMPARATOR
Intervention: SAPT alone (Control)
Number of subjects: 0
Study: 25669435

Group type: EXPERIMENTAL
Intervention: Nd-YAG laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical terbinafine
Number of subjects: 40
Study: 24135775

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 117

Group type: COMPARATOR
Intervention: control group (not specified)
Number of subjects: 117
Study: 21909316

Group type: EXPERIMENTAL
Intervention: Higher temperatures
Number of subjects: 12836

Group type: EXPERIMENTAL
Intervention: Heat humidity index
Number of subjects: 12836

Group type: EXPERIMENTAL
Intervention: Higher temperatures during specific months (June-September in Sylhet; April-September in Mirzapur)
Number of subjects: 12836
Study: 19066253

Group type: EXPERIMENTAL
Intervention: Comprehensive warm-up programme
Number of subjects: 1892

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1892
Study: 16564210

Group type: EXPERIMENTAL
Intervention: Extra early support measures
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 72
Study: 12569235

Group type: EXPERIMENTAL
Intervention: High intervention (n = 74)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Low intervention (n = 69)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control (n = 69)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: All groups (High, Low, Control)
Number of subjects: 212
Study: 11682403

Group type: COMPARATOR
Intervention: Remifentanil 10 microg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil 10 microg plus propofol 5 mg
Number of subjects: 120
Study: 9322450

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 80 mg/kg intravenously in divided doses
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no DCA)
Number of subjects: 80
Study: 7933639

Group type: EXPERIMENTAL
Intervention: Elemental diet (n = 21) composed of amino acid based with low fat content
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Semi-elemental diet (n = 19) which is oligopeptide-based and has higher fat content
Number of subjects: 40
Study: 3361096

Group type: EXPERIMENTAL
Intervention: Training group that received formal instructions in principles underlying figural relations problem solution (n = 24)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Self-instructed interactive group that received practice with figural relations training materials but no formal instruction (n = 21)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No-contact control group (n = 24)
Number of subjects: 69
Study: 30928180

Group type: EXPERIMENTAL
Intervention: 40IU intranasal oxytocin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28527771

Group type: EXPERIMENTAL
Intervention: Aspirin plus Clopidogrel (DAPT)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Aspirin alone (SAPT)
Number of subjects: 222
Study: 25872769

Group type: EXPERIMENTAL
Intervention: Short sleep condition (6.5 hr in bed)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Long sleep condition (10 hr in bed)
Number of subjects: 10
Study: 24274128

Group type: EXPERIMENTAL
Intervention: Educational intervention administered through the primary health care system, focusing on hazard awareness and preparedness for earthquakes and floods.
Number of subjects: 9200

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 9200
Study: 21599901

Group type: EXPERIMENTAL
Intervention: DESPATCH intervention (specialist decisional support, written feedback, academic detailing sessions, practice resources, evidence-based information)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evidence-based guidelines (control)
Number of subjects: 0
Study: 19230772

Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m² per day for 7 days every 28 days)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy)
Number of subjects: 358
Study: 17029304

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram diluted in 250 ml 0.9% saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 250 ml 0.9% saline (placebo)
Number of subjects: 0
Study: 12524634

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (OPD)
Number of subjects: 183
Study: 10947034

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Melatonin (0.1 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Temazepam (20 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Melatonin (all doses)
Number of subjects: 14
Study: 9102371

Group type: EXPERIMENTAL
Intervention: Conservative management (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interventionist management (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 8448756

Group type: EXPERIMENTAL
Intervention: Standard vincristine (V), dactinomycin (A), and cyclophosphamide (C)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Standard VA
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Intensive VA
Number of subjects: 999

Group type: COMPARATOR
Intervention: Repetitive-pulse VAC
Number of subjects: 999

Group type: COMPARATOR
Intervention: Repetitive-pulse VAdrC-VAC (Adr, Adriamycin [doxorubicin])
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis for Group III patients with cranial parameningeal sarcoma
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Same regimens as Group III
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: IRS‐II (including EA and all pelvic tumors)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Nonmetastatic patients in IRS‐II
Number of subjects: 999
Study: 30938839

Group type: EXPERIMENTAL
Intervention: Minipool nucleic acid testing (MP-NAT) using pools of 6 (MP6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minipool nucleic acid testing (MP-NAT) using pools of 16 (MP16)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minipool nucleic acid testing (MP-NAT)
Number of subjects: 0
Study: 28077419

Group type: EXPERIMENTAL
Intervention: Ergocalciferol (50,000 units once a week for 8 weeks)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 25387601

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (armA)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chemotherapy alone (armB)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Patients without liver surgery in armA
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Overall analysis of ETS as a predictor
Number of subjects: 138
Study: 23228201

Group type: EXPERIMENTAL
Intervention: Lithium 0.6‐1.2 mEq/L
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Lithium <0.6 mEq/L
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study: 21292635

Group type: EXPERIMENTAL
Intervention: Gene expression profiling
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 29-transcript predictive model
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Gene expression profile data
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Functional pathway analysis
Number of subjects: 162
Study: 18245031

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) internet intervention
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Depression information website
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 525
Study: 16155359

Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation (600 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vitamin E-coated dialyzer
Number of subjects: 31
Study: 12882653

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) therapy
Number of subjects: 10986

Group type: COMPARATOR
Intervention: NRTI-only therapy
Number of subjects: 10986
Study: 10371242

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg triazolam (Halcion)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 54
Study: 8977596

Group type: EXPERIMENTAL
Intervention: Single puffs via spacer (1200 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multiple puffs via spacer (3 x 4 puffs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single puffs with 20 second delay via spacer
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal spacer (prewashed)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Antistatic treated spacer (prewashed)
Number of subjects: 10
Study: 1675865

Group type: EXPERIMENTAL
Intervention: Pamidronate treatment (n = 76)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (n = 68)
Number of subjects: 144
Study: 6347278

Group type: EXPERIMENTAL
Intervention: RT + cyclophosphamide (C) for 12 monthly cycles
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: RT + cyclophosphamide/methotrexate/5‐fluorouracil (CMF) for 12 monthly cycles
Number of subjects: 805

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: C
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: CMF
Number of subjects: 805
Study: 31752838

Group type: EXPERIMENTAL
Intervention: Active surveillance of adverse events (AEs) through retrospective record review and post-operative visit observations.
Number of subjects: 5352

Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid dispensation as a proxy for VMMC-related infections.
Number of subjects: 5352
Study: 29846836

Group type: EXPERIMENTAL
Intervention: Savings‐led economic empowerment intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26975815

Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 40
Study: 25457690

Group type: EXPERIMENTAL
Intervention: Family‐to‐Family Support (FFS) program
Number of subjects: 46
Study: 21507661

Group type: EXPERIMENTAL
Intervention: PMDI
Number of subjects: 87
Study: 19328435

Group type: EXPERIMENTAL
Intervention: 200 mg b.i.d. celecoxib (Celebrex, Pfizer)
Number of subjects: 2528

Group type: EXPERIMENTAL
Intervention: 220 mg b.i.d. naproxen sodium (Aleve, Bayer)
Number of subjects: 2528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2528

Group type: EXPERIMENTAL
Intervention: All groups (celecoxib, naproxen, placebo)
Number of subjects: 2528
Study: 17138635

Group type: EXPERIMENTAL
Intervention: Vibration training (VT) applied at 50 Hz for 1 min on quadriceps, hamstring, and calf muscles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-vibration training (non-VT)
Number of subjects: 50
Study: 15103227

Group type: EXPERIMENTAL
Intervention: BIM‐23745
Number of subjects: 16

Group type: COMPARATOR
Intervention: octreotide
Number of subjects: 16
Study: 11453317

Group type: EXPERIMENTAL
Intervention: Untreated OSA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alcohol ingestion
Number of subjects: 38

Group type: COMPARATOR
Intervention: nCPAP (control for OSA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal night of sleep (control for sleep deprivation)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No alcohol (control for alcohol ingestion)
Number of subjects: 38
Study: 9744120

Group type: EXPERIMENTAL
Intervention: Sweat patches
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control period (urine testing)
Number of subjects: 48
Study: 8113844

Group type: EXPERIMENTAL
Intervention: NVB-P (vinorelbine and cisplatin)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: VDS-P (vindesine and cisplatin)
Number of subjects: 612

Group type: COMPARATOR
Intervention: NVB (vinorelbine alone)
Number of subjects: 612
Study: 2462221

Group type: EXPERIMENTAL
Intervention: Propranolol (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30467742

Group type: EXPERIMENTAL
Intervention: 4 mg/kg once every other week (QOW) dosing by intravenous infusion
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 4 mg/kg QOW dosing regimen
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 4 or 8 mg/kg once every 4 weeks dosing
Number of subjects: 23
Study: 28820468

Group type: EXPERIMENTAL
Intervention: Resveratrol 19.8 mg with Pegylated-Interferon-α2b and Ribavirin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with Pegylated-Interferon-α2b and Ribavirin
Number of subjects: 60
Study: 24470389

Group type: EXPERIMENTAL
Intervention: 3D planned reconstruction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional free form reconstruction
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3D planned reconstruction (mandibular body)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional free form reconstruction (mandibular body)
Number of subjects: 19
Study: 24367864

Group type: EXPERIMENTAL
Intervention: PSA-based screening for prostate cancer
Number of subjects: 0
Study: 21085891

Group type: EXPERIMENTAL
Intervention: CPAP 8 cmH₂O
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CPAP 12 cmH₂O
Number of subjects: 18

Group type: COMPARATOR
Intervention: CPAP sham (3 cmH₂O)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CPAP 5 cmH₂O
Number of subjects: 18
Study: 19496898

Group type: EXPERIMENTAL
Intervention: Twice-daily application of 0.1% tacrolimus
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Once-daily application of 0.1% tacrolimus
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (untreated lesions)
Number of subjects: 17
Study: 16330464

Group type: EXPERIMENTAL
Intervention: Combined antiplatelet plus moderate intensity anticoagulant therapy
Number of subjects: 311

Group type: COMPARATOR
Intervention: Anticoagulant therapy (target INR = 2.0-3.0)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Anticoagulant alone therapy
Number of subjects: 311
Study: 14636087

Group type: EXPERIMENTAL
Intervention: High force warm-up routine (high % 1RM, low repetition squats)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High power warm-up routine (low % 1RM, low repetition speed squats)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stretching warm-up routine (static stretches)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No activity (control condition)
Number of subjects: 32
Study: 10751104

Group type: EXPERIMENTAL
Intervention: Endurance training only (E)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Concurrent strength and endurance training (SE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Strength training only (S)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 45
Study: 9156531

Group type: EXPERIMENTAL
Intervention: Rapid transfusion (3 hours)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Slow transfusion (12 hours)
Number of subjects: 27
Study: 1638377

Group type: EXPERIMENTAL
Intervention: Tetracycline sclerotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Simple evacuation
Number of subjects: 45
Study: 6712367

Group type: EXPERIMENTAL
Intervention: Spironolactone therapy for two to four months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Chlorthalidone treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chlorthalidone after spironolactone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Uninterrupted chlorthalidone treatment
Number of subjects: 23
Study: 30075147

Group type: EXPERIMENTAL
Intervention: Five-session manualized caregiver intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 93
Study: 30183463

Group type: EXPERIMENTAL
Intervention: HRV biofeedback (HRV-BF) using resonant breathing
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 27923550

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg I.V. every 2 weeks for up to 1 year
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo every 2 weeks for up to 1 year
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 I.V. on days 1, 8, 29, and 36
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Etoposide 50 mg/m2 I.V. on days 1 to 5 and days 29 to 33
Number of subjects: 660
Study: 25916335

Group type: EXPERIMENTAL
Intervention: Proprietary nutritional supplement containing magnesium, riboflavin and Q10
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 23998158

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + enamel matrix derivative (EMD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) + connective tissue graft (CTG)
Number of subjects: 12
Study: 21362086

Group type: EXPERIMENTAL
Intervention: EPA+DHA supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19282313

Group type: EXPERIMENTAL
Intervention: Rhythm control (treated with amiodarone for at least 3 months prior to cardioversion and continued long-term if SR was restored)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Rate control (beta blockers and/or digoxin to reduce heart rate to <80 bpm at rest and <110 bpm after walking)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 61

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 61
Study: 17272503

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus antithymocyte globulin (ATG)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus ATG
Number of subjects: 134
Study: 15484727

Group type: EXPERIMENTAL
Intervention: Pea meal diet (200 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pea meal diet (100 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapeseed meal diet (100 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapeseed meal diet (200 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (soy-wheat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapeseed meal diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 0
Study: 12408203

Group type: EXPERIMENTAL
Intervention: Team-centered program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-on-one intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 0
Study: 9881990

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 96
Study: 8034831

Group type: EXPERIMENTAL
Intervention: Behavioral intervention methods
Number of subjects: 50

Group type: COMPARATOR
Intervention: Parental monitoring
Number of subjects: 50
Study: 2661658

Group type: EXPERIMENTAL
Intervention: cetraxate 200 mg four times daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: ranitidine 150 mg two times daily
Number of subjects: 49
Study: 29661156

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) with cognitive training and vitamin D supplementation (3 × 10,000 IU/wk.)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) with cognitive training and placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) without cognitive training and vitamin D supplementation (3 × 10,000 IU/wk.)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise (AE) and progressive resistance training (RT) without cognitive training and placebo
Number of subjects: 200

Group type: COMPARATOR
Intervention: Balance and toning control (BAT) intervention
Number of subjects: 200
Study: 28270229

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg every 4 months for five doses)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/day)
Number of subjects: 190
Study: 23572469

Group type: EXPERIMENTAL
Intervention: Parental folder
Number of subjects: 1634

Group type: COMPARATOR
Intervention: Expert valuation
Number of subjects: 1634